Its prevalence in developed countries is just about 0.3%. (Breteler, 532) the percentage exceeds to one percent in individuals above sixty years that increases to three percent for individuals that are older than eighty years. (Huse, 1450) Within the USA, Parkinson’s disease affects nearly hundred to one hundred eighty individuals out of every 100,000 individuals and shows a yearly occurrence of four to twenty out of every 100,000 individuals. The prevalence of the disease increases with the rise in the aging of population.
It has been estimated that there will be a rise in the occurrence of the disease in upcoming years; however its medical intrusions will participate to a great extent in combating with the extensive range of unmet requirements connected with the disorder.
Statistics show a market of $5.9bn in the worldwide retailing of Parkinsons disease restorative therapeutics that is far more than the last year’s values which used to be $4.6bn. Incomes gained from the authorized Parkinsons disease remedies all over the world (in major countries like America, England and France) found out to be more than $2.2 billion in 2006. A rise of revenues that is equivalent to approximately $6.4bn is anticipated by the end of 2015. (Metz, 251) Due to advancement in the therapies a reduction in the number of deaths due to Parkinsons disease is expected in next five to ten years.
The increase in the revenues is mainly due to the latest developments in drugs therapy that brings a reduction in the load of polypharmacy in individuals that are currently on the pharmacotherapy of the disease. A dynamic change in the market of Parkinson’s disease is expected mainly due to the leading therapeutics owned by the names like, GlaxoSmithKlines (GSKs), UCB-Schwarzs Neupro, Lundbeck’s Azilect and Teva etc. (Chrischilles, 410)
This has also been observed that a huge portfolio